Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mission: Cure
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject has been diagnosed with recurrent acute pancreatitis or chronic pancreatitis and a clinical decision has been made to treat the subject with one or more FDA-approved therapies, which may be being used off-label) to treat or prevent pancreatitis symptoms.
You may not be if
Participant has a known cystic fibrosis-associated CFTR mutation that would qualify them for standard Ivacaftor use.
Participant is unable to tolerate Ivacaftor due to prior adverse reactions.
Participant has severe liver dysfunction or baseline liver enzyme elevations that contraindicate Ivacaftor use, as determined by the treating physician.
Participant or parent/guardian is unwilling to comply with study procedures, including regular follow-up and data sharing.
Any other medical or psychological condition, in the judgment of the treating physician or counselor, that would make participation unsafe or not in the best interest of the participant.
Clareo Health | Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.
